___________________________________
Industrial Liaison Group:
Tel: +44 (0) 1235 778797
E-mail: [email protected]
The rise in antibiotic resistance has increased rapidly over the last decade, with pathogens such as pseudomonas aeruginosa carrying resistance to many drugs available. The recent COVID-19 pandemic has highlighted the importance of novel drugs to treat this species due to its association with ventilator-associated pneumonia, amongst other infections.
An attractive target for this pathogen is the LpxA enzyme which inhibits its growth. Although part of an existing series of enzymes in the same pathway – that have already been validated – this will represent a novel mode of action that circumvents existing target and class-based resistance mechanisms.
Optimised using macromolecular crystallography (MX) at Diamond, Evotec, X-Biotix Therapeutics and X-Chem explored this targeted therapy as an approach that is less likely to damage the healthy microbiota compared to broad-spectrum antibiotics. Find out what the study revealed.
Diamond Light Source is the UK's national synchrotron science facility, located at the Harwell Science and Innovation Campus in Oxfordshire.
Copyright © 2022 Diamond Light Source
Diamond Light Source Ltd
Diamond House
Harwell Science & Innovation Campus
Didcot
Oxfordshire
OX11 0DE
Diamond Light Source® and the Diamond logo are registered trademarks of Diamond Light Source Ltd
Registered in England and Wales at Diamond House, Harwell Science and Innovation Campus, Didcot, Oxfordshire, OX11 0DE, United Kingdom. Company number: 4375679. VAT number: 287 461 957. Economic Operators Registration and Identification (EORI) number: GB287461957003.
Industrial Liaison Office
